Several other clinical RCTs using pharmaceutical monotherapy for NASH and NASH fibrosis have failed to achieve primary endpoints, including the lysyl oxidase homolog 2 (LOXL2) inhibitor simtuzumab, the apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib, the dual antagonist of chemokine receptors 2 and 5 cenicriviroc, or the polyethylene glycol-conjugated analog of human fibroblast growth factor 21 pegbelfermin [87]. Here, MAP3K5 is linked to metabolic dysfunction-associated steatohepatitis.